Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection [version 2; peer review: 2 approved]

• Main Authors: Louise O. Downs, Anna L. McNaughton, Mariateresa de Cesare, M. Azim Ansari, Jacqueline Martin, Charles Woodrow, Rory Bowden, Jane Collier, Eleanor Barnes, Philippa C. Matthews
• Format: Article
• Language: English
• Published: Wellcome 2021-01-01
• Series: Wellcome Open Research
• Online Access: https://wellcomeopenresearch.org/articles/5-240/v2

Deep sequencing of the full-length hepatitis B virus (HBV) genome provides the opportunity to determine the extent to which viral diversity, genotype, polymorphisms, insertions and deletions may influence presentation and outcomes of disease. Increasing experience with analysis of HBV genomic data opens up the potential for using these data to inform insights into pathophysiology of infection and to underpin decision making in clinical practice. We here set out to undertake whole genome HBV sequencing from an adult who presented acutely unwell with a new diagnosis of HBV infection, and tested positive for both HBV anti-core IgM and IgG, possibly representing either acute hepatitis B infection (AHB) or chronic hepatitis B with an acute reactivation (CHB-AR). The distinction between these two scenarios may be important in predicting prognosis and underpinning treatment decisions, but can be challenging based on routine laboratory tests. Through application of deep whole-genome sequencing we typed the isolate as genotype-D1, and identified several minority variants including G1764A and G1986A substitutions in the pre-core promoter and pre-core regions, which support CHB-AR rather than AHB. In the longer term, enhanced deep sequencing data for HBV may provide improved evidence to distinguish between acute and chronic infection, to predict outcomes and to stratify treatment.